Merck seeks authorization for treatment

The company Merck has requested authorization for the emergency use of its experimental antiviral treatment against Covid-19 called molnupiravir, from the US Food and Drug Administration.

If authorized, this drug in capsule presentation would be the first oral antiviral treatment to combat COVID-19 presented and manufactured by Merck and Ridgeback Biotherapeutics.

This drug, presented in a study halted at the midpoint since it was working in more than 700 randomized patients, would serve to treat infected older adults who are at greater risk of being hospitalized.

The risk of hospitalization or death, in the interim analysis, the drug molnupiravir, reduces the risk by 50%.

Leave a Reply

Live Feed
Privacy, Disclaimer
Revies